peter attia on semaglutide 184 Semaglutide | Ask Huberman Lab

112 However, in recent years, the FDA has introduced the patient-focused drug development initiative, where patient-reported outcomes such as improvements in quality of life and healthy life years in MASH patients following treatment can serve as trial endpoints, potentially influencing final approval based on these data

Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management

[4] If supportive treatment is inadequate to manage this, renal replacement therapy (RRT) may be required

Some patients report thinking about food less often throughout the day, which reflects semaglutide's central nervous system effects on appetite regulation

Vitamin D injections are often recommended for individuals with low levels of this vitamin, particularly those with limited sun exposure or malabsorption issues

Couto, A